Roivant stock rises after Vtama meets main goal of 2nd phase 3 eczema study [Seeking Alpha]
Roivant Sciences Ltd. (ROIV)
Company Research
Source: Seeking Alpha
Roivant stock rises after Vtama meets main goal of 2nd phase 3 eczema studyMay 16, 2023 7:39 AM ETRoivant Sciences Ltd. (ROIV)By:RavikashSA EditorAsiaVisionDermavant Sciences' Vtama cream met the main goal of achieving clearer skin in a second phase 3 trial to treat adults and pediatric patients down to 2 years old with moderate to severe atopic dermatitis (AD).The trial, dubbed ADORING 1, enrolled407 children and adults with AD (also known as eczema) and evaluated topical Vtama (tapinarof) cream 1% versus vehicle cream.Dermavant, a unit of Roivant Sciences (NASDAQ:About 45.4% of patients on Vtama achieved the main goal, compared to 13.9% on the vehicle cream.About 55.8% patients treated with Vtama achieved 75% improvement in the Eczema Area and Severity Index (EASI75) compared to 22.9% on vehicle, at week 8. EASI75 was a secondary goal of the trial.The company added that 55.8% of patients â?¥12 years old, with a baseline Peak Pruritus Numeric Rating Scale (PP-NRS) score â?¥4, achiev
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary SarcoidosisBusiness Wire
- Roivant Sciences: Cashing In On Vants And Ventures [Seeking Alpha]Seeking Alpha
- OSR Holdings and SillaJen have entered into a Memorandum of Understanding to collaboratively pursue the development of innovative therapeutics and enter the U.S. market [Yahoo! Finance]Yahoo! Finance
- Roivant Sciences Ltd. (NASDAQ: ROIV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.MarketBeat
- Arbutus Biopharma jumps after patent victory in fight with Moderna [Seeking Alpha]Seeking Alpha
ROIV
Earnings
- 2/13/24 - Beat
ROIV
Sec Filings
- 4/24/24 - Form 4
- 4/24/24 - Form 4
- 4/23/24 - Form 4
- ROIV's page on the SEC website